BeyondSpring Inc.

What they do

BeyondSpring is a clinical-stage global biopharmaceutical company focused on developing therapies for high unmet medical needs. Its lead asset, Plinabulin, is a brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanisms, administered to over 700 cancer patients. The company is running a confirmatory global Phase 3 study (DUBLIN-4) in second- and third-line EGFR wild-type NSCLC after progression on immune checkpoint inhibitors, and is developing three preclinical small molecule immune agents. It also founded and retains an equity stake in SEED Therapeutics, which uses a targeted protein degradation platform and is partnered with Eli Lilly and Eisai.

Revenue drivers

• Plinabulin (no approved product revenue) — Plinabulin is the lead asset but is not approved or commercialized; reported revenue was $0.00 in 2023, 2024 and 2025.
• SEED Therapeutics equity stake — BeyondSpring founded and continues to own an equity stake in SEED, which uses a TPD platform and has partnerships with Eli Lilly and Eisai; no revenue contribution is disclosed in the excerpts.
• Preclinical small molecule immune agents — Three small molecule immune agents are in preclinical stages and generate no revenue.

Recent performance

Annual revenue was $1.4M in 2021 and 2022, then $0.00 in 2023, 2024 and 2025, with quarterly revenue of $0.00 through 2026-06-30. Net loss narrowed from $64.2M in 2021 to $1.0M in 2025, and diluted EPS improved from -$1.64 to -$0.02. At 2026-06-30, total assets were $14.6M, total liabilities $50.6M, shareholder equity was negative $35.6M, and cash and equivalents were $2.7M. Operating cash flow was -$19.8M in 2025 versus -$16.4M in 2024. The August 2026 8-K reported second-quarter 2026 results and cited ASCO 2026 Phase 2 data with a 58.0% 24-month overall survival rate.

Strategy

Management's stated lead priority is advancing regulatory, operational and financing preparations to initiate DUBLIN-4, a planned randomized, double-blind, 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous EGFR wild-type NSCLC after PD-1/PD-L1 progression. The company points to DUBLIN-3 results published in The Lancet Respiratory Medicine, ASCO 2026 Phase 2 data, and AACR 2026 preclinical ADC combination findings as support for Plinabulin's differentiated dendritic cell maturation mechanism. A leadership transition effective July 1, 2026 installed Min Qiu as CEO to align the organization around DUBLIN-4 and long-term value creation. BeyondSpring also maintains its SEED Therapeutics equity stake, where SEED advanced its RBM39 degrader into Phase 1 in January 2026.

Risks

• Going concern — The 10-Q states the company depends on obtaining necessary financing to fund working capital to continue as a going concern, with cash and equivalents of only $2.7M at 2026-06-30.
• No revenue and recurring losses — Revenue has been $0.00 since 2023 and the company expects to continue incurring significant operating losses for the foreseeable future.
• FDA Complete Response Letter — The 10-K risk factors reference a November 2021 Complete Response Letter regarding the NDA for Plinabulin with G-CSF for prevention of chemotherapy-induced neutropenia.
• Dependence on Plinabulin — The 10-K states the company depends substantially on the success of Plinabulin, which is being developed across multiple indications and has not been approved.

Outlook

Management says its priorities are advancing the regulatory, operational and financing preparations needed to initiate DUBLIN-4, the confirmatory Phase 3 study in non-squamous NSCLC post-ICI with overall survival as the primary endpoint. The company characterizes DUBLIN-4 as its lead clinical development priority for a potential path toward future regulatory submissions. It also cites ASCO 2026 Phase 2 and AACR 2026 preclinical ADC combination data as reinforcing Plinabulin's differentiated potential, while noting it expects continued significant operating losses.